Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

• Published in: The New England journal of medicine Vol. 381; no. 11; pp. 1001 - 1010
• Main Authors: Chen, Nan, Hao, Chuanming, Peng, Xiaomei, Lin, Hongli, Yin, Aiping, Hao, Li, Tao, Ye, Liang, Xinling, Liu, Zhengrong, Xing, Changying, Chen, Jianghua, Luo, Laimin, Zuo, Li, Liao, Yunhua, Liu, Bi-Cheng, Leong, Robert, Wang, Chunrong, Liu, Cameron, Neff, Thomas, Szczech, Lynda, Yu, Kin-Hung P
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 12.09.2019
• Subjects: Acidosis; Acidosis - chemically induced; Adult; Aged; Anemia; Anemia - drug therapy; Anemia - etiology; Cardiovascular disease; Cholesterol; Cholesterol - blood; Dialysis; Double-Blind Method; Erythropoiesis; Erythropoietin; Female; Glycine - adverse effects; Glycine - analogs & derivatives; Glycine - therapeutic use; Heart failure; Hematinics - adverse effects; Hematinics - therapeutic use; Hemodialysis; Hemoglobin; Hemoglobins - analysis; Hepcidin; Homeostasis; Humans; Hyperkalemia; Hyperkalemia - chemically induced; Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors; Hypoxia-inducible factors; Iron; Isoquinolines - adverse effects; Isoquinolines - therapeutic use; Kidney diseases; Male; Metabolic acidosis; Metabolism; Middle Aged; Patients; Prolyl hydroxylase; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - complications; China

This phase 3, randomized trial in China compared the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, with placebo for anemia in patients with CKD who were not undergoing dialysis. Roxadustat was superior to placebo in increasing and maintaining hemog...